196 related articles for article (PubMed ID: 18752043)
21. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
22. [Isolation of Id1 interaction protein in human prostate cancer].
Yu XL; Xie JX
Zhonghua Nan Ke Xue; 2008 Sep; 14(9):796-9. PubMed ID: 18998462
[TBL] [Abstract][Full Text] [Related]
23. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
[TBL] [Abstract][Full Text] [Related]
24. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
25. A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging.
Richter JR; Mahoney M; Warram JM; Samuel S; Zinn KR
Gene Ther; 2014 Oct; 21(10):897-902. PubMed ID: 25056609
[TBL] [Abstract][Full Text] [Related]
26. Increasing expression of GST-pi MIF, and ID1 genes in chemoresistant prostate cancer cells.
Yu DS; Hsieh DS; Chang SY
Arch Androl; 2006; 52(4):275-81. PubMed ID: 16728343
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor of differentiation 1 (Id1) and Id3 proteins play different roles in TGFβ effects on cell proliferation and migration in prostate cancer cells.
Strong N; Millena AC; Walker L; Chaudhary J; Khan SA
Prostate; 2013 May; 73(6):624-33. PubMed ID: 23060149
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues.
Wei H; Desouki MM; Lin S; Xiao D; Franklin RB; Feng P
Mol Cancer; 2008 Jan; 7():7. PubMed ID: 18208603
[TBL] [Abstract][Full Text] [Related]
29. Over expression of ID-1 in prostate cancer.
Ouyang XS; Wang X; Lee DT; Tsao SW; Wong YC
J Urol; 2002 Jun; 167(6):2598-602. PubMed ID: 11992094
[TBL] [Abstract][Full Text] [Related]
30. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
31. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
32. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
34. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
[TBL] [Abstract][Full Text] [Related]
35. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue.
Colombel M; Dante R; Bouvier R; Ribieras S; Pangaud C; Marechal JM; Lasne Y
J Urol; 1999 Sep; 162(3 Pt 1):927-30. PubMed ID: 10458410
[TBL] [Abstract][Full Text] [Related]
36. Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands.
Tsvetkova A; Todorova A; Todorov T; Georgiev G; Drandarska I; Mitev V
Pathol Oncol Res; 2015 Sep; 21(4):969-76. PubMed ID: 25753984
[TBL] [Abstract][Full Text] [Related]
37. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
39. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.
Singh S; Singh R; Singh UP; Rai SN; Novakovic KR; Chung LW; Didier PJ; Grizzle WE; Lillard JW
Int J Cancer; 2009 Nov; 125(10):2288-95. PubMed ID: 19610059
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
